Pneumonic plague is the form of plague in which the bacterium *Yersinia pestis* infects the lungs, causing severe pneumonia. It can develop after inhalation of infectious respiratory droplets or when infection elsewhere in the body spreads to the lungs. Unlike the usual flea-borne presentation of plague, pneumonic plague can pass directly between people through close respiratory contact. The disease progresses rapidly and is almost always fatal without treatment, but early effective antibiotic treatment substantially improves survival.
Cause and forms
Y. pestis is a bacterium maintained principally in cycles involving small mammals and their fleas. Human plague most commonly follows exposure to infected fleas or animals. Lung involvement occurs through two main pathways:
- Primary pneumonic plague begins when infectious droplets are inhaled and the lungs become the initial site of infection. Exposure can occur through close contact with an infected person or, less commonly, an infected animal, particularly a cat.
- Secondary pneumonic plague develops when bacteria reach the lungs through the bloodstream during another form of plague. It may complicate bubonic plague, characterized by painful, swollen lymph nodes, or septicemic plague, in which infection involves the bloodstream.
These terms describe the route by which the lungs become infected, not different bacterial species. Either form can produce infectious respiratory secretions once pulmonary disease develops.
Transmission
Person-to-person transmission occurs through respiratory droplets generated by a person with pneumonic plague, particularly during coughing. Transmission generally requires close contact with a symptomatic patient. It is not ordinarily associated with the long-range airborne spread characteristic of measles.
The risk of transmission depends on factors including proximity, duration of exposure, the patient's respiratory symptoms, and infection-control measures. Household members, caregivers, and healthcare personnel may be exposed during close contact without appropriate protection. Handling infected animals or tissues can also create exposure risks.
People with uncomplicated bubonic plague do not ordinarily transmit infection through respiratory droplets. This route becomes relevant if the lungs are involved. Recognizing pneumonic disease is therefore important both for individual care and for public health control.
Clinical features and progression
The incubation period of primary pneumonic plague is short, commonly about one to three days. Illness usually begins abruptly with fever, chills, headache, weakness, and other nonspecific symptoms. Respiratory features may appear early and worsen quickly:
- Cough, sometimes producing watery or bloody sputum;
- Shortness of breath;
- Chest pain;
- Rapidly progressive pneumonia and respiratory failure.
The early illness can resemble other acute respiratory infections. Bloody sputum is a recognized feature but is not present in every case, and its absence does not exclude the disease. Painful enlarged lymph nodes may be absent in primary pneumonic plague.
As infection advances, lung injury and systemic infection can lead to sepsis, shock, and failure of multiple organs. Untreated disease can become fatal within a few days of symptom onset. The short interval between initial symptoms and severe illness distinguishes it from many more slowly evolving respiratory infections.
Diagnosis
Diagnosis combines clinical findings, exposure history, and laboratory evidence. Relevant epidemiological clues include residence in or travel to an area where plague occurs, contact with sick or dead animals, and close contact with a suspected pneumonic plague case.
Laboratory confirmation may involve:
- Culture of Y. pestis from sputum, blood, or other appropriate specimens;
- Detection of bacterial genetic material by molecular testing;
- Detection of specific bacterial antigens in settings where suitable tests are available;
- Antibody testing, particularly when assessing paired samples collected at different stages of illness.
Microscopic appearances can raise suspicion but are not sufficient by themselves to establish the diagnosis. Chest radiography may demonstrate pneumonia, but the findings are not specific to plague.
The differential diagnosis includes other severe bacterial pneumonias and respiratory infections such as influenza. Because laboratory handling of Y. pestis carries an exposure risk, suspected specimens require appropriate laboratory biosafety procedures. Clinical management of suspected disease generally begins before final confirmation because diagnostic delays can have serious consequences.
Treatment and prognosis
Pneumonic plague is treatable with effective antibiotics. Agents used in established treatment protocols include aminoglycosides, such as gentamicin, and fluoroquinolones. Treatment selection depends on disease severity, patient characteristics, susceptibility information, and applicable clinical protocols.
Severe illness may require intensive supportive care, including treatment for shock and mechanical ventilation for respiratory failure. The timing of effective treatment is a major determinant of prognosis: treatment early in the illness offers a substantially better prospect of survival than treatment after advanced pneumonia or circulatory collapse has developed.
Naturally occurring resistance to commonly used plague treatments has been documented but is uncommon. Antimicrobial susceptibility testing can help characterize isolates and detect resistance.
Prevention and outbreak control
Control measures combine rapid case recognition, effective treatment, respiratory isolation, droplet precautions, and investigation of close contacts. Public health protocols include post-exposure antibiotics for qualifying contacts and monitoring during the period when illness could develop. These measures are intended to interrupt transmission before additional cases occur.
Public health surveillance also links human illness with animal and flea activity in areas where plague persists. Prevention of animal-associated exposure involves flea control, appropriate handling of potentially infected animals, and occupational protection.
A widely available vaccine is not part of routine pneumonic plague control. Historical plague vaccines have had important limitations, including uncertain or inadequate protection against pneumonic disease; newer vaccine approaches remain under development.
Epidemiology and history
Pneumonic plague is uncommon compared with bubonic plague, but its capacity for person-to-person transmission makes it especially important in outbreak investigation. Plague persists in natural animal reservoirs in several regions, with human cases reported particularly in parts of Africa and also in Asia and the Americas. Pneumonic cases may occur sporadically or in clusters.
The Manchurian plague epidemic of 1910–1911 was a major historical outbreak dominated by pneumonic transmission. It became an important episode in the development of respiratory isolation, protective measures, and coordinated epidemic response. In 2017, Madagascar experienced a large plague outbreak that included substantial pneumonic transmission and affected urban areas, illustrating how this usually uncommon disease can generate a major public health emergency.